CEVEC Pharmaceuticals GmbH

Koln, Germany

CEVEC Pharmaceuticals GmbH

Koln, Germany
SEARCH FILTERS
Time filter
Source Type

News Article | July 6, 2017
Site: globenewswire.com

Dublin, July 06, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biopharmaceutical Contract Manufacturing Market (2nd Edition), 2017-2027" report to their offering. The Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017-2027' report provides an extensive study of the contract manufacturing market for biopharmaceuticals. As the biotechnology industry continues to strive to maximize profits, outsourcing has emerged as a promising trend. The study features in-depth analysis, highlighting capabilities of a diverse set of biopharmaceutical CMOs. One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. In order to provide a detailed future outlook, our projections have been segmented on the basis of commonly outsourced business operations (Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs)), types of expression systems and key geographical regions. The base year for the report is 2017, and it provides a detailed market forecast for the period between 2017 and 2027. The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. For the purpose of the study, we invited more than 200 senior stakeholders in the industry to participate in a survey. This enabled us to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. In addition, the opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies). It is worth highlighting that the biopharmaceutical market is characterized by a huge unmet need for adequate manufacturing facilities and expertise. Given the inherent complexities associated with the development of biologics, the aforementioned need is likely to translate into promising business opportunities for CMOs. In addition to other elements, it provides information on the following: - The competitive market landscape and industry analysis based on a number of parameters, such as geographical location, scale of operation, type of biologics manufactured, expression systems used, type of bioreactors used, mode of operation of bioreactors and bioprocessing capacity. - Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance, information on its manufacturing service and facilities, partnerships and recent developments. - A detailed discussion on the key enablers, including certain niche sub-segments, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. - A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical contract service providers. - A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the market. The analysis takes into consideration the average capacities of small, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research. - Information on other aspects of biopharmaceutical outsourcing, which include the growing number of collaborations, partnerships and investments in facility expansions. - Affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Competitive Landscape 5. Biopharmaceutical Contract Manufacturing In North America 6. Biopharmaceutical Contract Manufacturing In Europe 7. Biopharmaceutical Contract Manufacturing In Asia And The Rest Of The World 8. Niche Sectors In Biopharmaceutical Contract Manufacturing 9. Case Study: Outsourcing Of Biosimilars 10. Recent Developments 11. Capacity Analysis 12. Survey Analysis 13. Opportunity Analysis 14. Swot Analysis 15. Future Of The Biopharmaceutical Cmo Market 16. Interview Transcripts 17. Appendix I Tabulated Data 18. Appendix Ii List Of Companies And Organizations - 3P Biopharmaceuticals - Aalto Scientific - AbbVie Contract Manufacturing - AbGenomics - Ablynx - Abzena - ACES Pharma - Acticor Biotech - Active Biotech - Adar Biotech - ADC Therapeutics - Adimab - Advanced BioScience Laboratories (ABL) - Advanced Biotherapeutics Consulting (ABC) - Affimed - Affinity Life Sciences - Agensys - Ajinomoto Althea - Albany Molecular Research (AMRI) - Alberta Cell Therapy Manufacturing - Alcami - Aldevron - Allele Biotechnology - Alliance Medical Products - Alligator Bioscience - Allozyne - ALMAC Group - Altaris Capital Partners - AmatsiQBiologicals - AmbioPharm - Ambrx - AmBTU - AMEGA Biotech - Amgen - Amneal Life Sciences - AMSBIO - Anogen - apceth Biopharma - Applied Biological Materials - Applied Viromics - Aptuit - Arabio - Asahi Glass - Aspyrian Therapeutics - Astellas Pharma - AstraZeneca - Asymchem - Athenex Pharma Solutions - Atlantic Bio GMP - AURA Biotechnologies - AUSTRIANOVA - AutekBio - Avecia - Avid Biologics - Avid Bioservices - Bachem - Baliopharm - Batavia Biosciences - Baxter BioPharma Solutions - Bayer - BCN Peptides - Beckman Research Institute - Beijing ABT Genetic Engineering Technology - Bharat Serums And Vaccines - BIBITEC - Bicycle Therapeutics - BINEX - Bio Elpida - Bioanalytical Sciences Department, Southern Research - BioCell - Biocon - BioConnection - Biofabri - Biogen-Idec - BioLineRx - Biological and Cellular GMP Manufacturing Facility, City of Hope - Biological E - Biological Process Development Facility, University of Nebraska - BioMARC - Biomatik - Biomay - BIOMEVA - BiondVax Pharmaceuticals - BioPharmaceuticals Australia - Biosynergy - Bio-Synthesis - BioTechLogic - BioTechnique - Biotechpharma - Biotecnol - Biotest - BioVectra - Biovian - Blue Stream Laboratories - Boehringer Ingelheim - Boehringer Ingelheim BioXcellence - Brammer Bio - Bristol-Myers Squibb - Bryllan - BSP Pharmaceuticals - Cambrex - CARBOGEN AMCIS - Catalent - Catalent Biologics - Catalent Pharma Solutions - Cedarburg Pharmaceuticals - Celgene - Cell and Gene Therapy Catapult - Cell Culture Company - Cell Essentials - Cell Therapies - Cell Therapy and Regenerative Medicine, University of Utah - Celldex Therapeutics - CELLforCURE - Cellin Technologies - Cells for Sight, Stem Cell Therapy Research Unit, University College London - Celltrion - Cellular Dynamics International (a FUJIFILM company) - Cellular Therapeutics - Cellular Therapy Integrated Service, Case Western Reserve University - Celonic - Center for Biocatalysis and Bioprocessing, University of Iowa - Center for Biomedical Engineering and Advanced Manufacturing, McMaster University - Center for Cell and Gene Processing, Takara Bio - Center for Cell and Gene Therapy, Baylor College of Medicine - Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia (CHOP) - Center of iPS Cell Research and Application, Kyoto University (CiRA) - Centre for Commercialization of Regenerative Medicine - Centrose - Century Pharmaceuticals - Cerbios-Pharma - CEVEC Pharmaceuticals - Charles River Laboratories - ChemCon - Chemi Peptides - ChemPartner - Children's GMP / GMP facility St. Jude Children's Research Hospital - ChromaCon - Cincinnati Children's Hospital Medical Center - CinnaGen - Clinical Biomanufacturing Facility, University of Oxford - Clinical Research Facility, South London and Maudsley - CMC Biologics - Cobra Biologics - Cognate BioServices - Coldstream Laboratories - Concord Biotech - Concortis - Cook Pharmica - Corden Pharma - Covance - Creative Biogene - Creative Biolabs - Cryosite - CytomX Therapeutics - Cytovance Biologics - Daiichi Sankyo - Dalton Pharma Services - Dishman Group - DMBio - Dow Pharmaceutical Solutions - Dutalys - EirGenix - Eli Lilly - Embio - EMD Serono - Emergent BioSolutions - Emerson - Encap Drug Delivery - Endo Pharmaceuticals - Epigen Biotech - Esperance Pharmaceuticals - EuBiologics - EUCODIS Bioscience - EUFETS - Eurofins Central Global Laboratory - Eurogentec - Euticals - Evonik - Fabion Pharmaceuticals - Ferro Pfanstiehl - FinVector - Formation Biologics - Formosa Laboratories - Foundation BioPharma - Fraunhofer Institute for Cell Therapy and Immunology IZI - French National Centre for Scientific Research, Université de Toulouse - Frontage Laboratories - F-star - FUJIFILM Diosynth Biotechnologies - Fusimab - Fusion Antibodies - Gadea Pharmaceutical Group - Gala Biotech - Gallus BioPharmaceuticals - Ganymed Pharmaceuticals - Gates Biomanufactuirng Facility - GE Healthcare - GEG Tech - Gene and Cell Therapy Lab, Institute of Translational Health Sciences - Gene Medicine Japan / Kobe Biomedical Accelerator - Gene Transfer Vector Core (GTVC) - Gene Transfer Vector Core, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary - Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies - Gene Vector and Virus Core, Stanford Medicine - GeneCure Biotechnologies - GeneDetect - Genentech - Genethon - GenIbet Biopharmaceuticals - Genmab - Génopoïétic - GenVec - Gilead Sciences - GIPharma - Glenmark Pharmaceuticals - Glycotope Biotechnology - GNH India - Goodwin Biotechnology - GOSH Cellular Therapy Laboratories, University College of London - GP Pharm - Grand River Aseptic Manufacturing - Great Point Partners - GreenPak Biotech - Grünenthal - GSEx, The Robinson Research Institute, University of Adelaide - GSK - GSK-Domantis - GTP Technology - Guy's and St Thomas' Facility - HALIX - Harvest Moon Pharmaceuticals - Health Biotech - Health Sciences Authority - Heidelberg Pharma - Hepalink - Hetero Drugs - Histocell - Hisun Pharmaceuticals USA - Ho Research Consortium - Hong Kong Institute of Biotechnology - Hope Center Viral Vectors Core, Washington University School of Medicine - iBIOSOURCE - Icagen - IDDI - IDT Biologika - Igenica Biotherapeutics - ImClone Systems - ImmunoGen - Immunomedics - INC Research - Indian Immunologicals - Inhibrx - Inno Biologics - Innovent Biologics - Intas Pharmaceuticals - Integrity Bio - International Joint Cancer Institute, Military Medical University - Intertek - Istituto Biochimico Italiano Giovanni Lorenzini - JHL Biotech - John Goldmann Centre for Cellular Therapy, Imperial College London - Julphar Gulf Pharmaceutical Industries - KABS Pharmaceutical Services - Kairos Therapeutics - Kamat Pharmatech - KBI Biopharma - Kemwell Biopharma - Laboratory for Cell and Gene Medicine, Stanford University - LAMPIRE Biological Laboratories - Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec) - LFB BIOMANUFACTURING - Lindis Biotech - Lonza - LuinaBio - MabPlex - MacroGenics - Maine Biotechnology Services - MassBiologics - MaSTherCell - MBI International - MediaPharma - MedImmune - Medix Biochemica - Menarini Biotech - Merck - Meridian Life Science - Merrimack - Merro Pharmaceutical - Mersana Therapeutics - Merus - MGH Vector Core (Massachusetts General Hospital Neuroscience Center) - MicroBiopharm Japan - Microbix Biosystems - Millennium Pharmaceuticals - Minomic International - Mitsubishi Gas Chemical Company - Moderna Therapeutics - Molecular and Cellular Therapeutics, University of Minnesota - Molecular Partners - MolMed - MPI Research - Multispan - Mycenax Biotech - Nantes Gene Therapy Institute - Nascent Biologics - National Cancer Institute (NCI) - National Research Council of Canada - NBE Therapeutics - Neuland Laboratories - NeuroCure (Viral Core Facility) - NeuroFx - Newcastle Cellular Therapies, University of Newcastle - NextCell - NHS Blood and Transplant - NHSBT Birmingham - Nikon Cell And Gene Therapy Contract Manufacturing - Nitto Avecia Pharma Services - Nordic Nanovector - Norwegian Institute of Public Health - Nova Laboratories - Novartis - Novasep - Novex Innovations - NovImmune - Numab - Oasmia Pharmaceutical - OcellO - OctoPlus - Okairos (GSK subsidiary) - Olon - Omnia Biologics - OncoMed - OncoQuest - OsoBio - OXB Solutions (a business of Oxford BioMedica) - Oxford BioMedica - Oxford BioTherapeutics - Oxford Genetics - Pacific GMP - Paktis Antibody Services - Palatin Technologies - Pamlico BioPharma - Panacea Biotec - Paragon Bioservices - Parexel - Particle Sciences - PATH - Patheon - PCI Services (Biotec Services International) - PCT, a Caladrius company - Penn Vector Core, University of Pennsylvania - Pfizer - Pfizer CentreOne - PharmAbcine - PharmaBio - PharmaCell - Pharmedartis - PharmiCell - Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital - Philochem - PhotoBiotics - Pierre Fabre - Piramal Pharma Solutions - PlasmidFactory - Polymun Scientific - Polypeptide Group - Praxis Pharmaceutical - Precision Antibody - Precision Biologics - PREMAS Biotech - ProBioGen - Productos Bio-Logicos - Profectus BioSciences - Progenics Pharmaceuticals - ProJect Pharmaceutics - ProMab Biotechnologies - Protheragen - Provantage End-to-End Services (Merck Millipore) - PX'Therapeutics - Pyramid Labs - Quintiles - Raymond G Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia - Rayne's Cell Therapy Suite, King's College London - Receptor Logic - Redwood Bioscience - Regeneron Pharmaceuticals - Reliance Life Sciences - Rentschler Biotechnologie - Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation - Richter-Helm BioLogics - Rimedion - Robertson Clinical and Translational Cell Therapy, Duke University - Roche - Roslin Cell Therapies - Roswell Park Cancer Institute - Royal DSM - Royal Free, CCGTT - SAB Technology - SAFC - Samsung BioLogics - Sandoz - Sanofi, CEPiA (Commercial & External Partnership, Industrial Affairs) - Sanofi-Aventis - Sanquin Pharmaceutical Services - School of Medicine, University of Utah - Scientific Protein Laboratories - Sea Lane Biotechnologies - Seattle Genetics - Selexys Pharmaceuticals - Senn Chemicals - SGS Life Science Services - Shire - SignaGen Laboratories - Singota Solutions - Sirion Biotech - SNBTS Cellular Therapy Facility - Societa Italiana Corticosteroidi - Sorrento Therapeutics - Spirogen - ST Pharm - Stem CentRx - Sutro Biopharma - Sydney Cell and Gene Therapy - Symbiosis Pharmaceutical Services - Symbiosis, the Analytical Company - SynCo Bio Partners - Synergys Biotherapeutics - Syngene - SYNIMMUNE - Synthon - Sypharma - System Biosciences - Takara Bio - Takeda - The Chemistry Research Solution - The Lentiviral Laboratory, USC School of Pharmacy - The Native Antigen Company - The Vector Core, University of North Carolina - Therapure Biopharma (Therapure Biomanufacturing) - THERAVECTYS - Thermo Fisher Scientific - Toyobo Biologics - Translational Sciences - TranXenoGen - Trenzyme - Trion Pharma - Triphase Accelerator Corporation - UC Davis GMP Laboratory - UCB-Celltech - UCLA Human Gene and Cell Therapy - UMN Pharma - University of Alabama Fermentation Facility - University of Manchester - University of Oxford Clinical BioManufacturing Facility - University of Texas - Upstate Stem Cell cGMP Facility, University of Rochester - Valerion Therapeutics - Valneva - Vectalys - Vector Biolabs - Vector Core / GMP Facility, UC Davis - Vector Core Lab / Human Applications Lab, Powell Gene Therapy Center, University of Florida - Vector Core of Gene Therapy Laboratory of Nantes - Vector Production Facility, Indiana University - Vecura (Karolinska University Hospital ) - Vetter Pharma International - VGXI - Vibalogics - Vigene Biosciences - Viral Vector Core / Clinical Manufacturing Facility, Nationwide Children's Hospital - Viral Vector Core, Duke University - Viral Vector Core, Sanford Burnham Prebys Medical Discovery Institute - Viral Vector Core, University of Iowa Carver College of Medicine - Viral Vector Core, University of Massachusetts Medical School (UMMS) - Virovek - Vista Biologicals - VIVEbioTECH - Wacker Biotech - Waisman Biomanufacturing - WIL Research - Wockhardt - Wolfson Gene Therapy Unit, University College of London - WuXi AppTec - Wyeth - X-BODY Biosciences - Xellbiogene - Xencor - YposKesi - Zhejiang HISUN Pharmaceuticals - Zhengyang Gene Technology - Zumutor Biologics - Zydus Cadila - Zymeworks - ZymoGenetics - Zyngenia For more information about this report visit https://www.researchandmarkets.com/research/m9qmm2/biopharmaceutical


The present invention relates to a genetically modified cell line with reduced expression of GnTIVa/b and/or GnTV, a method for the production of glycoproteins having N-glycans with a reduced number of tri- and/or tetra-antennary N-glcyans using said cell line, and respective glycoproteins.


Genzel Y.,Max Planck Institute for Dynamics of Complex Technical Systems | Behrendt I.,Max Planck Institute for Dynamics of Complex Technical Systems | Rodig J.,Max Planck Institute for Dynamics of Complex Technical Systems | Rapp E.,Max Planck Institute for Dynamics of Complex Technical Systems | And 5 more authors.
Applied Microbiology and Biotechnology | Year: 2013

Forced by major drawbacks of egg-based influenza virus production, several studies focused on the establishment and optimization of cell-based production systems. Among numerous possible host cell lines from duck, monkey, canine, chicken, mouse, and human origin, only a few will meet regulatory requirements, accomplish industrial standards, and result in high virus titers. From primary virus isolation up to large-scale manufacturing of human vaccines, however, the most logical choice seems to be the use of human cell lines. For this reason, we evaluated the recently established CAP cell line derived from human amniocytes for its potential in influenza virus production in suspension culture in small scale shaker flask and stirred tank bioreactor experiments. Different human and animal influenza viruses could be adapted to produce hemagglutination (HA) titers of at least 2.0 log10 HA units/100 μL without further process optimization. Adjusting trypsin activity as well as infection conditions (multiplicity of infection, infection medium) resulted in HA titers of up to 3.2 log10 HA units/100 μL and maximum cell-specific virus productivities of 6,400 virions/cell (for human influenza A/PR/8/34 as a reference). Surface membrane expression of sialyloligosaccharides as well as HA N-glycosylation patterns were characterized. Overall, experimental results clearly demonstrate the potential of CAP cells for achieving high virus yields for different influenza strains and the option to introduce a highly attractive fully characterized human cell line compliant with regulatory and industrial requirements as an alternative for influenza virus vaccine production. © 2012 Springer-Verlag.


Patent
CEVEC Pharmaceuticals GmbH | Date: 2014-12-19

The present invention relates to a method for the production of a permanent human cell line, wherein isolated primary human cells are transfected simultaneously with a sequence allowing the expression of at least one cell transforming factor and a sequence allowing the expression of at least one recombinant polypeptide.


The present invention relates to recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as cell lines that are genetically modified to overexpress a -galactoside -2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of said recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.


Patent
CEVEC Pharmaceuticals GmbH | Date: 2013-10-18

The present invention relates to a method for the production of human Cytomegalovirus (HCMV) particles, the method including the steps of: (a) contacting and thereby infecting a permanent human amniocyte cell with HCMV, (b) incubating the amniocyte cell, (c) allowing expression of HCMV particles, and (d) isolating of the HCMV particles, wherein the permanent human amniocyte cell expresses the adenoviral gene products E1A and E1B and wherein the amniocyte cells are cultured in serum free medium. Furthermore, the present invention relates to HCMV particles produced by the method of the present invention as well as to a HCMV based vaccine comprising the HCMV particles, the use of the HCMV particles for use in the preparation of a HCMV based vaccine and the HCMV particles for use in the preparation of a therapeutic or diagnostic agent for the prevention or treatment of a HCMV related disease.


Patent
CEVEC Pharmaceuticals GmbH | Date: 2014-04-23

The present invention relates to a method for the production of HCMV particles, the method including the steps of: (a) contacting and thereby infecting a permanent human amniocyte cell with HCMV, (b) incubating the amniocyte cell, (c) allowing expression of HCMV particles, and (d) isolating of the HCMV particles, wherein the permanent human amniocyte cell expresses the adenoviral gene products E1A and E1B. Furthermore, the present invention relates HCMV particles produced by the method of the present invention as well as to a HCMV based vaccine comprising the HCMV particles, the use of the HCMV particles for use in the preparation of a HCMV based vaccine and the HCMV particles for use in the preparation of a therapeutic or diagnostic agent for the prevention or treatment of a HCMV related disease.


Trademark
CEVEC Pharmaceuticals GmbH | Date: 2011-10-11

Chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of chemicals, biologicals and biochemicals, namely, preparations and reagents for non medical use, in particular for scientific, research, laboratory, industrial and commercial purposes; chemical, biological and biochemical additives, preparations and reagents for research and characterisation of diseases for non-medical purposes; chemical, biological and biochemical additives, preparations and reagents, namely, cell lines, cells, proteins and polypeptides, for scientific and medical research and development of pharmaceuticals; chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of medicines and pharmaceuticals; cultures of microorganisms other than for medical and veterinary use; cell lines, cells and amino acids for laboratory or research use; nucleic acid sequences, proteins and polypaptides for other than medical and veterinary use; diagnostic reagents and preparations comprising proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for scientific, research, laboratory, and commercial purposes for the development of medicines and for use in the manufacture of medicines and pharmaceuticals. Medicines, chemical, biological and biochemical preparations and proteins for the treatment of cancer, tumourous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardiovascular diseases, except thyreostatica and cough and cold medicines; pharmaceutical and veterinary preparations and reagents for use in the treatment of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except thyreostatica and cough and cold medicines; chemical, biological and biochemical reagents for medical and veterinary purposes, except thyreostatica and cough and cold medicines; diagnostic and analytic preparations for medical and veterinary purposes; cell lines, cells, diagnostic proteins and polypeptides for medical or clinical use; nucleic acid sequences, diagnostic proteins, polypeptides and chemical reagents for medical and veterinary purposes; amino acids for medical or veterinary purposes; diagnostic reagents and preparations, namely, microorganisms, proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for medical, veterinary and diagnostic purposes, except thyreostatica and cough and cold medicines. Scientific and industrial research, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; research and development of medicines, diagnostic and analytic preparations, methods of therapy and expression systems; scientific and technological consulting services, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; industrial consulting services, namely, consultancy pertaining to pharmacology; breeding, recovery, optimisation, synthesis and modification of cell culture lines, cells, microorganisms, polypeptides, proteins, nucleotides, nucleic acids for scientific, research, laboratory, industrial and commercial purposes, namely, for use in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics, for the development of medicines and for use in the manufacture of medicines and pharmaceuticals.


Patent
CEVEC Pharmaceuticals GmbH | Date: 2011-08-16

The present invention relates to a method for the production of an influenza virus-based vaccine using permanent human amniocyte cells, as well as the use of a permanent human amniocyte cell for the production of a influenza virus-based vaccine.


Loading CEVEC Pharmaceuticals GmbH collaborators
Loading CEVEC Pharmaceuticals GmbH collaborators